COPB2 suppresses cell proliferation and induces cell cycle arrest in human colon cancer by regulating cell cycle‑related proteins

Wang,Yan; Chai,Zhi; Wang,Min; Jin,Yanling; Yang,Aijun; Li,Min

doi:10.3892/etm.2017.5506

COPB2 suppresses cell proliferation and induces cell cycle arrest in human colon cancer by regulating cell cycle‑related proteins

Authors:
- Yan Wang
- Zhi Chai
- Min Wang
- Yanling Jin
- Aijun Yang
- Min Li
View Affiliations

Affiliations: Institute of Integrated Traditional Chinese and Western Medicine, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Telemedicine Consultation Centre, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China
Published online on: November 13, 2017 https://doi.org/10.3892/etm.2017.5506
Pages: 777-784
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Coat proteins (COPs), including the major types clathrin, COPI and COPII, play a considerable role in intracellular transport by initiating the formation of transport vesicles. Coatomer protein complex subunit β2 (COPB2) is one of the seven subunits that make up a COPI complex. In the present study, we found that COPB2 was highly expressed in human colon cancer specimens. However, to date, there have been no reports describing the functions of COPB2 in human colon cancer cells. In this study, we analyzed the functions of COPB2 in the proliferation and cell cycle arrest of human RKO and HCT116 colon cancer cells by using lentivirus‑mediated RNAi infection. Our results demonstrated that the silencing of COPB2 in vitro could inhibit the proliferation and colony formation abilities of RKO and HCT116 cells. Furthermore, measurement of cell cycle distribution indicated that the downregulation of COPB2 could induce G0/G1 or S phase cell cycle arrest by regulating cell cycle‑related proteins. In conclusion, our results suggest that COPB2 plays a key role in the proliferation and cell cycle progression of human RKO and HCT116 colon cancer cells, thus indicating that COPB2 might be a potential therapeutic target for the treatment of human colon cancer.

View Figures

View References

1	Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China. CA Cancer J Clin. 66:115–132. 2015. View Article : Google Scholar
5	Wang S, Zhai Y, Pang X, Niu T, Ding YH, Dong MQ, Hsu VW, Sun Z and Sun F: Structural characterization of coatomer in its cytosolic state. Protein Cell. 7:586–600. 2016. View Article : Google Scholar : PubMed/NCBI
6	Hara-Kuge S, Kuge O, Orci L, Amherdt M, Ravazzola M, Wieland FT and Rothman JE: En Bloc incorporation of coatomer subunits during the assembly of COP-coated vesicles. J Cell Biol. 124:883–892. 1994. View Article : Google Scholar : PubMed/NCBI
7	Kuge O, Hara-Kuge S, Orci L, Ravazzola M, Amherdt M, Tanigawa G, Wieland FT and Rothman JE: zeta-COP, a subunit of coatomer, is required for COP-coated vesicle assembly. J Cell Biol. 123:1727–1734. 1993. View Article : Google Scholar : PubMed/NCBI
8	Orcl L, Palmer DJ, Amherdt M and Rothman JE: Coated vesicle assembly in the Golgi requires only coatomer and ARF proteins from the cytosol. Nature. 364:732–734. 1993. View Article : Google Scholar : PubMed/NCBI
9	Presley JF, Ward TH, Pfeifer AC, Siggia ED, Phair RD and Lippincott-Schwartz J: Dissection of COPI and Arf1 dynamics in vivo and role in Golgi membrane transport. Nature. 417:187–193. 2002. View Article : Google Scholar : PubMed/NCBI
10	Beck R, Rawet M, Wieland FT and Cassel D: The COPI system: Molecular mechanisms and function. FEBS Lett. 583:2701–2709. 2009. View Article : Google Scholar : PubMed/NCBI
11	Lee MC, Miller EA, Goldberg J, Orci L and Schekman R: Bi-directional protein transport between the ER and Golgi. Annu Rev Cell Dev Biol. 20:87–123. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ruokun C, Yake X, Fengdong Y, Xinting W, Laijun S and Xianzhi L: Lentivirus-mediated silencing of HSDL2 suppresses cell proliferation in human gliomas. Tumour Biol. 37:15065–15077. 2016. View Article : Google Scholar : PubMed/NCBI
13	Wang D, Sun SQ, Yu YH, Wu WZ, Yang SL and Tan JM: Suppression of SCIN inhibits human prostate cancer cell proliferation and induces G0/G1 phase arrest. Int J Oncol. 44:161–166. 2014. View Article : Google Scholar : PubMed/NCBI
14	Bie CQ, Liu XY, Cao MR, Huang QY, Tang HJ, Wang M, Cao GL, Yi TZ, Wu SL, Xu WJ and Tang SH: Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression. Oncotarget. 7:79305–79318. 2016.PubMed/NCBI
15	Tomuleasa C, Soritau O, Fischer-Fodor E, Pop T, Susman S, Mosteanu O, Petrushev B, Aldea M, Acalovschi M, Irimie A and Kacso G: Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 4:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
16	Soritau O, Tomuleasa C, Aldea M, Petrushev B, Susman S, Gheban D, Ioani H, Cosis A, Brie I, Irimie A, et al: Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J BUON. 16:282–289. 2011.PubMed/NCBI
17	Buck EA, Haley JD, Thomson S, Mulvihill MJ, Epstein DM and Miglarese MR: Combination anti-cancer therapy WO patent application 2013152252. October 10–2013
18	Zhang Z, Wang T, Liu Z, Tang S, Yue M, Feng S, Hu M, Xuan L and Chen Y: Small interfering RNA targeting of the survivin gene inhibits human tumor cell growth in vitro. Exp Ther Med. 14:35–42. 2017. View Article : Google Scholar : PubMed/NCBI
19	Yang Y and Huang S: Discuss the strengths and weaknesses between tumour biotherapy and chemoradiotherapy. Med Infor. 24:3503–3504. 2011.
20	Arora N, Gupta A and Singh PP: Biological agents in gastrointestinal cancers: Adverse effects and their management. J Gastrointest Oncol. 8:485–498. 2017. View Article : Google Scholar : PubMed/NCBI
21	Sudo H, Tsuji AB, Sugyo A, Kohda M, Sogawa C, Yoshida C, Harada YN, Hino O and Saga T: Knockdown of COPA, identified by loss of function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model. Genomics. 95:210–216. 2010. View Article : Google Scholar : PubMed/NCBI
22	Stenbeck G, Harter C, Brecht A, Herrmann D, Lottspeich F, Orci L and Wieland FT: beta'-COP, a novel subunit of coatomer. EMBO J. 12:2841–2855. 1993.PubMed/NCBI
23	Mi Y, Yu M, Zhang L, Sun C, Wei B, Ding W, Zhu Y, Tang J, Xia G and Zhu L: COPB2 is upregulated in prostate cancer and regulates PC-3 cell proliferation, cell cycle, and apoptosis. Arch Med Res. 47:411–418. 2016. View Article : Google Scholar : PubMed/NCBI